Subroto B Chatterjee

US Patent:

6511979, Jan 28, 2003

Filed:

Jul 22, 1999

Appl. No.:

09/359023

Inventors:

Subroto Chatterjee - Columbia MD

Assignee:

Johns Hopkins University - Baltimore MD

International Classification:

A61K 31535

US Classification:

5142378, 514315, 514428

Abstract:

The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCer1â4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.

US Patent:

6528272, Mar 4, 2003

Filed:

Feb 5, 1998

Appl. No.:

09/019435

Inventors:

Subroto Chatterjee - Columbia MD

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

G01N 3353

US Classification:

435 732, 435 71, 435 733, 435 737, 435 79, 435 792, 435 794, 435180, 435975, 436518, 436524, 436531, 436541, 436808, 4242361, 4242431, 530359

Abstract:

A rapid, simple, and inexpensive sandwich enzyme-linked receptor based immunodot assay detects pathogens or pathogenic products in test samples using receptors for a characteristic component of the pathogen. This assay is widely applicable because it is highly specific, it does not require special equipment, and the results can be obtained within a few hours with the naked eye. Since the lipid-based receptors have a long-shelf life, they can be easily stored and used for a long time.

US Patent:

6713057, Mar 30, 2004

Filed:

Feb 23, 2000

Appl. No.:

09/511532

Inventors:

Subroto Chatterjee - Columbia MD

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 3846

US Classification:

424 946, 514 13

Abstract:

Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.

US Patent:

7230094, Jun 12, 2007

Filed:

May 27, 2003

Appl. No.:

10/446519

Inventors:

Subroto B. Chatterjee - Columbia MD, US

International Classification:

C07H 21/04
C12N 15/00
C12N 5/00

US Classification:

536 245, 4353201, 435325

Abstract:

The present invention provides novel antisense ribozymes useful for inhibiting the activity of neutral sphingomyelinase. Also provided are methods for reducing the activity of neutral sphingomyelinase, as well as methods for reducing apoptosis and atherosclerosis using the ribozymes of the invention.

US Patent:

8492351, Jul 23, 2013

Filed:

Jun 22, 2009

Appl. No.:

12/488965

Inventors:

Subroto Chatterjee - Columbia MD, US
Mark S. Butler - Brisbane, AU
Brinda Somanadhan - Singapore, SG

International Classification:

A01N 43/04
A61K 31/70

US Classification:

514 25

Abstract:

The present invention provides novel compounds with hypocholesteremic activity from crude (EO) extracts and methods of use. The invention also provides nutraceuticals.

US Patent:

8614064, Dec 24, 2013

Filed:

May 24, 2004

Appl. No.:

10/557283

Inventors:

Subroto Chatterjee - Columbia MD, US
Peter O. Kwiterovich - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

G01N 33/53
C07K 14/775

US Classification:

435 71, 530359

Abstract:

The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.

US Patent:

20020160484, Oct 31, 2002

Filed:

Mar 31, 1999

Appl. No.:

09/282879

Inventors:

SUBROTO CHATTERJEE - COLUMBIA MD, US

International Classification:

C12N009/16

US Classification:

435/196000, 435/320100, 435/325000, 536/023200

Abstract:

Isolated nucleic acids are provided that encode human neutral sphingomyelinase (N-SMase) and N-SMase fragments and derivatives capable of hybridizing to such N-SMase-encoding nucleic acids. The invention also includes isolated recombinant human neutral sphingomyelinase (N-SMase) and N-SMase fragments and derivatives are also provided. Novel assays are also provided to identify compounds useful in the diagnosis or treatment of human neutral sphingomyelinase related disorders.

US Patent:

20050079998, Apr 14, 2005

Filed:

Aug 13, 2003

Appl. No.:

10/640502

Inventors:

Subroto Chatterjee - Columbia MD, US

Assignee:

Johns Hopkins University - Baltimore MD

International Classification:

A61K038/00
A61K031/685
A61K031/401
A61K031/366

US Classification:

514002000, 514423000, 514460000, 514548000, 514078000

Abstract:

Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.